Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update


In this 2023 FN CPG update, changes from the 2017 CPG included two conditional recommendations regarding earlier discontinuation of empiric antibacterial therapy in clinically well and afebrile patients with low-risk FN if blood cultures remain negative at 48 hours despite no evidence of marrow recovery and pre-emptive antifungal therapy for IFD high-risk patients not receiving antimold prophylaxis. The panel also created a good practice statement to initiate FN CPG-consistent empiric antibacterial therapy as soon as possible in clinically unstable febrile patients.


View our guidance library

Explore guidance for providing optimal supportive care to children receiving cancer treatments or undergoing bone marrow transplant.

Stay connected

Sign up to receive the iPOG Network quarterly newsletter!